Salzman Group Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Salzman group ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Salzman Group Ltd Today - Breaking & Trending Today

Judge ponders 'door closing statute' in diversity claim

Judge ponders ‘door closing statute’ in diversity claim-
A preliminary determination on whether an Illinois “door closing statute” blocked companies incorporated in Pennsylvania and Israel from pursuing a diversity claim in Chicago because they weren’t registered under the Illinois Business Corporation. ....

United States , Illinois Business Corporation , Salzman Group Ltd , Bracken Data Inc , Ellie Pharmaceuticals , Illinois Business Corporation Act , Israel Based Salzman Group , Pennsylvania Based Bracken Data , Thomas Guel , Dirksen Courthouse ,

Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

South Korea , United States , Robert Farrell , Rho Gtpase , Acta Biomater , Company Or Claritas , Claritas Pharmaceuticals , Salzman Group Ltd , Salzman Group , Claritas Pharmaceuticals Inc , Salzman Group Inc , Venture Exchange , Salzman Group Pty , Regulation Services Provider , Orphan Drug Designation , Clinical Study , Wound Healing , Skin Ulcers , Wound Healing Indications , Skin Ulcer , Wound Healing Indication , Nitrogen Species Releasing Hydrogel , Enhanced Wound Healing , Annu Int Conf , Med Biol , Oxide Releasing Hyaluronic Acid ,

Claritas Completes Acquisition of Exclusive Worldwide

Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the Disease. ....

United States , South Korea , Robert Farrell , Company Or Claritas , Claritas Pharmaceuticals , Salzman Group To Claritas , Salzman Group Inc , Salzman Group , Claritas Pharmaceuticals Inc , Salzman Group Ltd , Venture Exchange , Salzman Group Pty , Clarita Development Plan , License Amendment , Nitric Oxide Releasing , License Agreement , Will Develop , Nitric Oxide Therapy , Clarita President , Positive Data , Validated Animal Model , Disease Progression , Near Total Relief , Acute Symptoms , Potential Cure , Safety Profile ,

Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , South Korea , Grand View , Salvador Moncada , Robert Farrell , Pahand Pphnarelethal , Adrianh Chester , Magdih Yacoub , Company Or Claritas , Claritas Pharmaceuticals , Salzman Group To Claritas , View Research , Salzman Group Ltd , Salzman Group , Claritas Pharmaceuticals Inc , Salzman Group Inc , Venture Exchange , Regulation Services Provider , Salzman Group Pty , Clarita Development Plan , License Amendment , Nitric Oxide Releasing , License Agreement , Will Develop , Nitric Oxide Therapy , Clarita President ,

Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
Claritas Pharmaceuticals, Inc.April 14, 2021 GMT
SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into a binding Letter of Intent (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzman Group Pty. Ltd. (an Australian corporation), (collectively, the “Salzman Group”), under which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of pulmonary arterial hypertension (“PAH”). The Company expects that definitive agreements will be executed by May 15, 2021. Closing of the transaction is sub ....

South Australia , United States , South Korea , San Francisco , Salvador Moncada , Robert Farrell , Adrianh Chester , Magdih Yacoub , Company Or Claritas , Claritas Pharmaceuticals , View Research , Salzman Group Inc , Salzman Group Ltd , Salzman Group , Claritas Pharmaceuticals Inc , Venture Exchange , Salzman Group Pty , Regulation Services Provider , Clarita Development Plan , Nitric Oxide Releasing , License Agreement , Will Develop , Nitric Oxide Therapy , Both Viral Infections , Clarita President , Nitric Oxide ,